 |
|
|
| |
SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Paul Kwo,1 Michael Bennett,2 Stanley Wang,3 Hugo E. Vargas,4 David Wyles,5 J. Scott Overcash,6 Peter Ruane,7 Benedict Maliakkal,8 Asma Siddique,9 Bal Raj Bhandari,10 Fred Poordad,11 Ran Liu,3 Chih-Wei Lin,3 Teresa I. Ng,3 Federico J. Mensa,3 Jens Kort3
1Indiana University School of Medicine, Indianapolis, IN, USA; 2San Diego Digestive Disease Consultants, Inc., and Medical Associates Research Group, Inc., San Diego, CA, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Mayo Clinic, Phoenix, AZ, USA; 5University of California San Diego, La Jolla, CA, USA; 6eStudySite, San Diego, CA, USA; 7Ruane Medical & Liver Health Institute, Los Angeles, CA, USA; 8University of Rochester Medical Center, Rochester, NY, USA; 9Virginia Mason Hospital and Medical Center, Seattle, WA, USA;
10Gastroenterology & Nutritional Medical Services, Bastrop, LA, USA; 11Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA
|
| |
|
|
|
|
|
